Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 1:12 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 9,138 matching trials from the live ClinicalTrials.gov search.
Filters: Rochester, Minnesota Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II

NCT06271577
View directory record Official record
Conditions
Myocardial Infarction, Ischemia, Myocardial Ischemia, Heart Diseases, Cardiovascular Diseases, Vascular Diseases, Heart Attack, Heart Failure
Interventions
AliveCor 12-lead ECG
Device
Lead sponsor
AliveCor
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
Rochester, Minnesota • Murray, Utah
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Nov 1, 2026, 1:12 AM EST
Completed Phase 2 Interventional

A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis

NCT03897257
View directory record Official record
Conditions
Tinea Pedis
Interventions
UHE-103A1 cream, UHE-103A2 cream, UHE-103B cream, UHE-103A1B cream, UHE-103A2B cream
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
16 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
San Diego, California • Melbourne, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Nov 1, 2026, 1:12 AM EST
Terminated Phase 1 Interventional

Evaluate Use of Mangosteen Juice Added to Usual Care in Reducing Risk of Recurrent Atrial Fibrillation

NCT00951301
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
mangosteen juice, placebo juice
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Nov 1, 2026, 1:12 AM EST
Completed Phase 1 Interventional

Study to Evaluate the Effects of RM-131 in Patients With Chronic Constipation

NCT02137642
View directory record Official record
Conditions
Chronic Constipation
Interventions
RM-131, Placebo
Drug
Lead sponsor
Motus Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Nov 1, 2026, 1:12 AM EST
Not listed Phase 2 Interventional

A Study of the Safety, Efficacy and Tolerability of Nexvax-2 in Patients With Celiac Disease (CeD)

NCT03644069
View directory record Official record
Conditions
Celiac Disease, Celiac, Intestinal Disease, Malabsorption Syndromes, Gastrointestinal Disease, Digestive System Disease, Gluten Sensitivity, Autoimmune Diseases
Interventions
Nexvax2, Placebo
Biological
Lead sponsor
ImmusanT, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
28
States / cities
Walnut Creek, California • Stamford, Connecticut • Lighthouse PT, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Nov 1, 2026, 1:12 AM EST
Completed Phase 2 Interventional Results available

18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy

NCT03778294
View directory record Official record
Conditions
Glioblastoma, Malignant Glioma
Interventions
Computed Tomography, Fluorodopa F 18, Magnetic Resonance Imaging, Positron Emission Tomography, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Temozolomide
Procedure · Other · Radiation + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Nov 1, 2026, 1:12 AM EST
Terminated Not applicable Interventional

Efficacy and Safety Study of the Estech COBRA® Surgical System to Treat Patients With a History of Irregular Heart Beats

NCT01683045
View directory record Official record
Conditions
Persistent Atrial Fibrillation
Interventions
The Estech COBRA® Surgical System
Device
Lead sponsor
Endoscopic Technologies, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Mesa, Arizona • Hartford, Connecticut • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Nov 1, 2026, 1:12 AM EST
Completed Phase 2 Interventional Results available

Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients

NCT00110266
View directory record Official record
Conditions
Myelodysplastic Syndrome, Iron Overload
Interventions
Deferasirox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Concord, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Nov 1, 2026, 1:12 AM EST
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Research for Individualized Therapeutics in Rare Genetic Disease

NCT05236595
View directory record Official record
Conditions
Rare Genetic Disease, Undiagnosed Diseases
Interventions
Individualized drug matching per genetic disease
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Minneota, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Nov 1, 2026, 1:12 AM EST
Completed Phase 2 Interventional Results available

Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT00398112
View directory record Official record
Conditions
B-cell Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
Interventions
sunitinib malate, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Nov 1, 2026, 1:12 AM EST
Recruiting No phase listed Observational

A Study Of MCG In Cardiac Amyloidosis

NCT07218705
View directory record Official record
Conditions
Amyloidosis
Interventions
SandboxAQ CardiAQ Magnetocardiography
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Nov 1, 2026, 1:12 AM EST
Completed Phase 3 Interventional Results available

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

NCT01150045
View directory record Official record
Conditions
Colorectal Cancer
Interventions
celecoxib, 5-fluorouracil, placebo, oxaliplatin, leucovorin
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
2,527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
826
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 536 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Nov 1, 2026, 1:12 AM EST
Completed Phase 3 Interventional Results available

The Kiva® System as a Vertebral Augmentation Treatment

NCT01123512
View directory record Official record
Conditions
Spinal Fractures, Fractures, Compression, Back Injuries
Interventions
Vertebral augmentation
Device
Lead sponsor
Benvenue Medical, Inc.
Industry
Eligibility
50 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Encinitas, California • Mountain View, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Nov 1, 2026, 1:12 AM EST
Completed Early Phase 1 Interventional

Impact of Ascorbic Acid Treatment on the Development and Treatment of Vasodilation in Cardiac Surgery

NCT03744702
View directory record Official record
Conditions
Vasoplegia
Interventions
Ascorbic Acid
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Nov 1, 2026, 1:12 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Tissue Destruction and Healing in Celiac Disease

NCT05680012
View directory record Official record
Conditions
Celiac Disease
Interventions
Gluten containing snack bar
Dietary Supplement
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
3
States / cities
Pasadena, California • Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Nov 1, 2026, 1:12 AM EST
Active, not recruiting Phase 3 Interventional

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

NCT05633602
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Chemotherapy, Pembrolizumab, Ramucirumab
Drug · Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
566
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 442 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Nov 1, 2026, 1:12 AM EST
Completed Phase 4 Interventional

This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque.

NCT00380939
View directory record Official record
Conditions
Coronary Arteriosclerosis
Interventions
Atorvastatin, Pravastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 75 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
36
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2006 · Synced Nov 1, 2026, 1:12 AM EST
Completed Phase 3 Interventional

WelChol® With Metformin in Treating Patients With Type 2 Diabetes

NCT00147719
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Colesevelam hydrochloride
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
46
States / cities
Jonesboro, Arkansas • Beverly Hills, California • Carmichael, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2012 · Synced Nov 1, 2026, 1:12 AM EST
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT06430801
View directory record Official record
Conditions
Crohn's Disease
Interventions
IV Tulisokibart, SC Tulisokibart, IV Placebo, SC Placebo
Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years to 80 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
87
States / cities
Dothan, Alabama • Phoenix, Arizona • Sun City, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 1, 2026, 1:12 AM EST
Completed Phase 1 Interventional

CCI-779 in Treating Patients With Advanced Solid Tumors

NCT00003712
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
temsirolimus
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
2
States / cities
Rochester, Minnesota • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Nov 1, 2026, 1:12 AM EST
Terminated Phase 1Phase 2 Interventional Results available

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

NCT03917381
View directory record Official record
Conditions
Solid Tumors
Interventions
Acasunlimab, Acasunlimab in combination with docetaxel (in a single expansion cohort), Acasunlimab in combination with pembrolizumab (in a separate expansion cohort), Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)
Biological
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • New Haven, Connecticut • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Nov 1, 2026, 1:12 AM EST
Active, not recruiting Phase 3 Interventional

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

NCT04092283
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
829
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 549 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 1, 2026, 1:12 AM EST
Completed Phase 1 Interventional

Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer

NCT01460537
View directory record Official record
Conditions
Neoplasms
Interventions
Gemcitabine, BAY80-6946, Cisplatin, NaCl, BAY80-6964 fixed dose
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Tampa, Florida • Rochester, Minnesota • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Nov 1, 2026, 1:12 AM EST
Recruiting No phase listed Observational

Bladder Bank (a Prospective Banking Study)

NCT06109857
View directory record Official record
Conditions
Bladder Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Nov 1, 2026, 1:12 AM EST